Literature DB >> 24658652

Apoptosis and KI 67 index correlate with preoperative chemotherapy efficacy and better predict the survival of gastric cancer patients with combined therapy.

Aiwen Wu, Yongning Jia, Bin Dong, Lei Tang, Yiqiang Liu, Hong Du, Peng Yuan, Peide Dong, Jiafu Ji.   

Abstract

PURPOSE: T he correlation of apoptotic and proliferation index with preoperative chemotherapy efficacy was investigated. Their prognostic value was also explored.
METHODS: 167 patients were enrolled, curative gastrectomy and D2 lymphadenectomy were performed, and a total of 12 cycles of perioperative mFOLFOX7 chemotherapy was recommended. Apoptosis index (AI) and Ki67 index (KI) in surgical specimens were detected.
RESULTS: Apoptosis index, KI and AI/KI were significantly different between patients received perioperative chemotherapy and surgery (CS group, n = 84) and those who received only surgery and postoperative chemotherapy (S group, n = 83). In the CS group, number of patients who received 2, 4, 6 cycles of preoperative chemotherapy were, respectively, 28, 53 and 3. AI, KI and AI/KI were closely related to pathological response. Cutoff value of AI and AI/KI for response separated CS group patients into two subgroups with significant different prognosis and picked up more potential responders than pathological evaluation, especially in pathological response evaluation grade 1a–b.
CONCLUSIONS: Apoptosis index, KI and AI/KI are significantly related to chemotherapy efficacy and prognosis of gastric cancer patients who received perioperative chemotherapy and radical gastrectomy. They could be used in combination with pathological response evaluation to distinguish more potential responders.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24658652     DOI: 10.1007/s00280-014-2410-3

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  7 in total

1.  Expression and significance of annexin A2 in patients with gastric adenocarcinoma and the association with E-cadherin.

Authors:  Yuehua Han; Jun Ye; Ying Dong; Zhipeng Xu; Qin DU
Journal:  Exp Ther Med       Date:  2015-06-10       Impact factor: 2.447

2.  ypTNM staging after neoadjuvant chemotherapy in the Chinese gastric cancer population: an evaluation on the prognostic value of the AJCC eighth edition cancer staging system.

Authors:  Ziyu Li; Yinkui Wang; Fei Shan; Xiangji Ying; Zhouqiao Wu; Kan Xue; Rulin Miao; Yan Zhang; Jiafu Ji
Journal:  Gastric Cancer       Date:  2018-05-10       Impact factor: 7.370

Review 3.  Preoperative Chemotherapy for Gastric Cancer: Personal Interventions and Precision Medicine.

Authors:  Wei Xu; Maneesh K Beeharry; Wentao Liu; Min Yan; Zhenggang Zhu
Journal:  Biomed Res Int       Date:  2016-12-25       Impact factor: 3.411

4.  Prognostic impact of Ki-67 in patients with gastric cancer-the importance of depth of invasion and histologic differentiation.

Authors:  Gyung Hyuck Ko; Se-Il Go; Won Sup Lee; Jeong-Hee Lee; Sang-Ho Jeong; Young-Joon Lee; Soon Chan Hong; Woo Song Ha
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889

5.  Ki-67/MKI67 as a Predictive Biomarker for Clinical Outcome in Gastric Cancer Patients: an Updated Meta-analysis and Systematic Review involving 53 Studies and 7078 Patients.

Authors:  Dan-Dan Xiong; Chu-Mei Zeng; Ling Jiang; Dian-Zhong Luo; Gang Chen
Journal:  J Cancer       Date:  2019-08-29       Impact factor: 4.207

6.  Expression of miR-652-3p and Effect on Apoptosis and Drug Sensitivity in Pediatric Acute Lymphoblastic Leukemia.

Authors:  Qian Jiang; Xiaojing Lu; Pengli Huang; Chao Gao; Xiaoxi Zhao; Tianyu Xing; Gang Li; Shilai Bao; Huyong Zheng
Journal:  Biomed Res Int       Date:  2018-06-05       Impact factor: 3.411

7.  Ki-67 labeling index as a prognostic marker in advanced stomach cancer.

Authors:  Sang Hyuk Seo; Kwang Hee Kim; Sang Hoon Oh; Yunseon Choi; Ki Jung Ahn; Ji Young Lee; Sang Min Lee; Jisun Park; Woo Gyeong Kim
Journal:  Ann Surg Treat Res       Date:  2018-12-26       Impact factor: 1.859

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.